T1	Participants 106 149	advanced non-small-cell lung cancer (NSCLC)
T2	Participants 183 191	Hellenic
T3	Participants 551 675	Since July 1996, 198 patients with non-operable NSCLC and measurable disease without previous chemotherapy entered the trial
